[Phosphate therapy of recurrent calcium calculus disease. Current status].
D002129:Calcium Oxalate / Q000652:urine*; D002130:Calcium Phosphates / Q000652:urine*; D002131:Calcium Pyrophosphate / Q000652:urine; D006801:Humans; D010710:Phosphates / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D012008:Recurrence; D014545:Urinary Calculi / Q000188:drug therapy* / Q000652:urine
D002130:Calcium Phosphates; D010710:Phosphates; C485828:alpha-tricalcium phosphate; C485830:tetracalcium phosphate; D002129:Calcium Oxalate; C485838:calcium phosphate, monobasic, anhydrous; C020243:calcium phosphate; C485829:calcium phosphate, dibasic, anhydrous; D002131:Calcium Pyrophosphate
Phosphattherapie des rezidivierenden Kalziumstein-Leidens. Eine Standortbestimmung.